CRISPR Therapeutics (CRSP) Jumps 9.6% on Biotech Rally

CRISPR Therapeutics AG (NASDAQ:CRSP) is one of the 10 Stocks Going Wild.

Crispr Therapeutics rallied for a second day on Wednesday, adding 9.6 percent to close at $60.08 apiece, tracking the rally in the biotechnology sector and the broader market.

During the session, the biotechnology industry rose by 3.58 percent amid a flurry of developments in the sector. Meanwhile, Wall Street’s main indices all finished in the green territory.

Additionally, investors may have begun repositioning portfolios ahead of the release of second-quarter earnings results. Based on its historical reporting dates, CRISPR Therapeutics AG (NASDAQ:CRSP) will announce its financial and operating results in the first week of August.

In the first quarter of the year, CRISPR Therapeutics AG (NASDAQ:CRSP) widened its net loss by 17 percent to $136 million from $116 million previously.

Revenues, however, jumped by 71.6 percent to $865 million from $504 million year-on-year.

While we acknowledge the potential of CRSP as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.